The mostcommon pathology group indicative of anti-VEGF therapy was macular edema (60.12%),with 48.25% of diabetic etiology and 11.09% secondary to venous occlusions, followedby MNV (21.4%) with exudative AMD accounting for 12.45% of the injected eyes. The gene discussed is VEGFA; the disease is age-related macular degeneration.